[Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
Heparin Cofactor II (HCII) is a glycoprotein in human plasma which inactivates thrombin rapidly in the presence of dermatan sulfate. Inhibition occurs by formation of a stable equimolar complex between HCII and thrombin. HCII association with thrombotic events has not always been observed, thus decreased HCII does not appear to be a strong risk factor for thromboembolic events. Reduced HCII levels have been detected in different clinical conditions, such as hepatic failure, disseminated intravascular coagulation, thalasemina, sickle cell anemia. Increased physiological levels have been found in pregnant women and oral contraception. In our laboratory, we measured HCII plasmatic levels in the normal Buenos Aires city population and in patients under different clinical conditions, such as sepsis, diabetis, burns, oral anticoagulation and in patients treated with heparin, hyperhomcysteinemia in whom septic and diabetic patients showed decreased values. HCII thrombin inhibition possibly takes place in extravascular sites where dermatan sulfate is present. HCII activity would be important in the regulation of wound healing, inflammation, or neuronal development.
Rossi
E B
EB
Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina. lht@qb.fcen.UBA.ar
Duboscq
C L
CL
Kordich
L C
LC
D020147:Coagulation Protein Disorders; D003871:Dermatan Sulfate / Q000502:physiology; D015844:Heparin Cofactor II / Q000737:chemistry / Q000172:deficiency / Q000502:physiology*; D006801:Humans; D012016:Reference Values; D015842:Serine Proteinase Inhibitors / Q000502:physiology*; D013917:Thrombin / Q000037:antagonists & inhibitors*
D015842:Serine Proteinase Inhibitors; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D013917:Thrombin